NasdaqGS - Delayed Quote • USD
Phathom Pharmaceuticals, Inc. (PHAT)
At close: April 23 at 4:00 PM EDT
After hours: April 23 at 7:16 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 7 | 7 | 7 | 7 |
| Avg. Estimate | -1.24 | -1.21 | -4.59 | -3.24 |
| Low Estimate | -1.63 | -1.66 | -5.94 | -4.34 |
| High Estimate | -1.01 | -0.81 | -3.34 | -2.17 |
| Year Ago EPS | -0.89 | -0.84 | -3.93 | -4.59 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 7 | 7 | 7 | 7 |
| Avg. Estimate | 2.05M | 6.07M | 44.81M | 173.66M |
| Low Estimate | 830k | 4.49M | 34M | 133.12M |
| High Estimate | 3.5M | 7.35M | 53.9M | 237.34M |
| Year Ago Sales | -- | -- | 682k | 44.81M |
| Sales Growth (year/est) | -- | -- | 6,470.40% | 287.50% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -1.26 | -0.98 | -0.89 | -1.08 |
| EPS Actual | -0.89 | -0.84 | -0.76 | -1.39 |
| Difference | 0.37 | 0.14 | 0.13 | -0.31 |
| Surprise % | 29.40% | 14.30% | 14.60% | -28.70% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -1.24 | -1.21 | -4.59 | -3.24 |
| 7 Days Ago | -1.22 | -1.19 | -4.57 | -3.21 |
| 30 Days Ago | -1.18 | -1.14 | -4.33 | -3.11 |
| 60 Days Ago | -1.24 | -1.22 | -4.56 | -3.14 |
| 90 Days Ago | -1.26 | -1.23 | -4.54 | -3.06 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | 1 | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | 1 | 1 | 1 |
Growth Estimates
| CURRENCY IN USD | PHAT | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -39.30% | -- | -- | 0.40% |
| Next Qtr. | -44.00% | -- | -- | 9.90% |
| Current Year | -16.80% | -- | -- | 4.30% |
| Next Year | 29.40% | -- | -- | 13.40% |
| Next 5 Years (per annum) | -- | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | Needham: Buy to Buy | 4/19/2024 |
| Reiterates | Needham: Buy to Buy | 4/12/2024 |
| Reiterates | Needham: Buy to Buy | 4/11/2024 |
| Reiterates | Needham: Buy to Buy | 4/5/2024 |
| Reiterates | Needham: Buy to Buy | 4/1/2024 |
| Reiterates | Needham: Buy to Buy | 3/22/2024 |
Related Tickers
RYTM Rhythm Pharmaceuticals, Inc.
40.00
+2.54%
ELVN Enliven Therapeutics, Inc.
17.37
-1.42%
ARQT Arcutis Biotherapeutics, Inc.
8.74
-2.24%
BMEA Biomea Fusion, Inc.
10.98
+1.39%
DAWN Day One Biopharmaceuticals, Inc.
16.64
+8.19%
CGEM Cullinan Therapeutics, Inc.
16.67
+6.65%
PLRX Pliant Therapeutics, Inc.
12.52
-0.63%
VRCA Verrica Pharmaceuticals Inc.
6.85
+0.88%
TERN Terns Pharmaceuticals, Inc.
4.6900
-2.70%
URGN UroGen Pharma Ltd.
14.53
+1.11%